Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522311 | 0.84 | NR3C2 (0.49) | NR3C2POLBALDH1A1 | |
| SCHEMBL4530965 | 0.84 | NR3C2 (0.65) | NR3C2POLBXIAPBIRC2ALDH1A1 | |
| SCHEMBL753825 | 0.83 | NR3C2 (0.57) | NR3C2POLBSLC9A1ARCACNA1B | |
| SCHEMBL2267353 | 0.80 | NR3C2 (0.56) | NR3C2SLC9A1XIAPBIRC2AR | |
| SCHEMBL755350 | 0.79 | NR3C2 (0.70) | NR3C2ARCACNA1BAPBA1 | |
| SCHEMBL755856 | 0.78 | NR3C2 (0.54) | NR3C2ARCACNA1BAPBA1 | |
| SCHEMBL753047 | 0.78 | NR3C2 (0.47) | NR3C2SLC9A1ARCACNA1BAPBA1 | |
| SCHEMBL756843 | 0.77 | NR3C2 (0.63) | NR3C2SLC9A1ARALDH1A1CACNA1B | |
| SCHEMBL16978177 | 0.75 | NR3C2 (0.65) | NR3C2POLBSLC9A1ARCACNA1B | |
| SCHEMBL754239 | 0.73 | NR3C2 (0.71) | NR3C2POLBARCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| CN-101379048-B | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORP | 2012-03-21 | — | — | CN | disclosed |
| CN-101379048-A | Benzo oxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | NR3C2 1/4885POLB 3875/4885HDAC2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.